Replies to post #252734 on Innovation Pharmaceuticals Inc (IPIX)

[wsbc]

Maybe re-familiarize yourself with the NASDAQ uplisting requirements, along with AMEX.

Then do the math concerning shares outstanding, and the deal-ballpark concerning the existing TS.

Without knowing the actual structure of what's on the table, we can't get precise, but you can estimate.

I think if you plug in realistic numbers based on the valuation of product over time, given the estimated life of the patent, you'll reach a number that should put us in the vicinity of being able to meet uplisting criteria for the NASDAQ.

https://listingcenter.nasdaq.com/assets/initialguide.pdf

LEO is the wildcard here. He's going to be driving to what could appear to be an unrealistic sum, based on a likely emotional attachment to IPIX and the current state of progress across 2 indications (with the TS having been announced to include IBD interest as well). The numbers and applications are actually on his side, however.

The emotional sunk-cost associated with this could be the catalyst to whether something moves or not. They're shopping now. They feel they can do better than what's currently on the table.

Cross your fingers.